Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery,
chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC …

Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant
rise in the number of TC cases has been observed for the past few decades. TCs are one of …

Follicular thyroid carcinoma (FTC) has different clinicopathological characteristics than
papillary thyroid carcinoma. However, there are no independent systems to predict cancer …

Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …

Thyroid cancer (TC) is the most frequent malignancy of the endocrine system. Apatinib, as
an anti-angiogenic agent, has been applied in the therapy of several cancers. However, the …

The cumulative evidence over the past decades has shown that the incidence of
differentiated thyroid carcinoma (DTC) has exponentially increased. Approximately 10% of …

Thyroid cancer (TC) is the most common endocrine malignancy. TC is classified as
differentiated TC (DTC), which includes papillary and follicular subtypes and Hürthle cell …

Introduction Multikinase inhibitor (MKI) treatments have shown efficacy in progressive
radioiodine refractory thyroid cancers (RAIR-TC), but most patients experienced substantial …

Objectives Our aim was to describe our experience in using apatinib as treatment for
radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC). Methods Forty-seven …

Purpose Management of progressive, metastatic radioactive iodine refractory differentiated
thyroid cancer (RAIR-DTC) has been a great challenge due to its poor prognosis and limited …